
    
      Single arm, phase II study, MR (Magnetic Resonance Imaging) - based IGRT (Image-guided
      radiotherapy) of prostate cancer.

      Primary endpoint: Grade 2+ GI (gastrointestinal) and genitourinary (GU) toxicity after 2
      years.
    
  